

# Real World Evidence and HTA – Experiences with IQWiG

Dr. Carsten Schwenke

Karmeliterweg 42

D-13465 Berlin

+49-30-60409712

[consult@scosis.de](mailto:consult@scosis.de)

[www.scosis.de](http://www.scosis.de)

[www.scosis.com](http://www.scosis.com)



# Overview

- Some definitions
- IQWiG and RWD
- Examples
- Final remarks




# Amount of additional benefit

- **§ 5 (7) Size of additional benefit**
  - Major
  - Considerable
  - Minor
  - Not quantifiable
  - No additional benefit
  - Benefit lower than benefit of GBA-defined comparator



# Confidence in benefit

- **Confidence in benefit (IQWiG Methods paper 5.0 chapter 3.1.4)**
  - **Proof**
    - Statistical significance in  $\geq 2$  RCTs with high confidence in benefit
  - **Hint**
    - Statistical significance in one RCT with high confidence in benefit or in  $\geq 2$  RCTs with moderate confidence in benefit
  - **Clue**
    - Statistical significance in one RCT with moderate confidence in benefit or in  $\geq 2$  RCTs with low confidence in benefit
  - **No confidence**



# AMNOG - Principle

- Studies with the highest evidence to be reported
  - If RCTs available, then these are to be reported
  - If no RCT is available, the studies with next highest evidence to be reported
    - E.g. single-arm studies
    - E.g. non-randomized studies



# What is ment by RWE?

- Real world data vs. Real world evidence
- RWD = Data used for decision making that is not collected in RCTs
- RWD can be obtained when the drug is marketed => as request with time retriction of decision by G-BA
- Evidence level
  - 1 = RCT (or meta-analyses based on RCTs)
    - Internal validity => causal relationship can be concluded
  - 2 to 4 = observational studies (cohort / case control studies and case series)
    - Timely relationship can be concluded
    - External validity
    - Low costs
    - No randomization => treatment effect depends on similarity of groups



# Issues with RWD

- Statistically

- Many sources of bias

- selection bias, missingness not at random, etc.

- No causal interpretation possible

- Non-statistically

- Generation of data

- Transparency

- Validity

- Data quality



# RWD in AMNOG

- Main application in AMNOG dossier
  - prevalence and incidence in Module 3
  - Patient pathways and use of drugs
    - maybe relevant in price negotiations
  - Supportive data in Module 4
- Single-arm trials
  - In absence of RCTs
  - Accepted in special circumstances
    - HepC and HIV applications (historical comparisons)
    - Vismodegib





# RWD – IQWiG position

- RCTs are study designs with least issues
- All other designs are worse
  - Huge effort needed to control for confounders
  - Issues in literature search (search terms, filters)
  - RWD not necessarily with higher external validity
  - External validity is useless, if based on low quality data
  - Effectiveness cannot be assessed by RWD
    - Even should not be assessed at all


Source: Windeler J (2015): Real World data – ein Gewinn für die Nutzenbewertung?;  
Herbstsymposium 2015



# RWD – IQWiG position

- Most publications of RWD state, that they need to be confirmed in RCTs...
- Requirements on RWD not defined
- Adaptive pathways regarded doubtful
- Registries most often do not collect QoL data
- RWD is needed for
  - The assessment of prevalence and incidence
  - Cost of the comparators and/or best supportive care

Source: Windeler J (2015): Real World data – ein Gewinn für die Nutzenbewertung?; Herbstsymposium 2015



# Vismodegib – Module 4

## ■ Studies included by Roche

- SHH4476g (ERIVANCE, Phase II, single-arm, pivotal)
- MO25616 (STEVIE, Phase II, single-arm)
- Study SHH4811g (US-EAP, Expanded access study, single-arm)
- Study SHH3925g (Phase I, single-arm)
- Extension study of patients from Phase I and II
- RegiSONIC (observational, single-arm)
- NIELS (observational, single-arm)
- Viscusi and Hanke 2015 (observational, single-arm)

Source: Nutzendossier zu Vismodegib



# Vismodegib – IQWiG

## ■ Studies included by Roche

- SHH4476g (ERIVANCE, Phase II, single-arm, pivotal)
- MO25616 (STEVIE, Phase II, single-arm)
- Study SHH4811g (US-EAP, Expanded access study, single-arm)
- Study SHH3925g (Phase I, single-arm)
- Extension study of patients from Phase I and II
- RegiSONIC (observational, single-arm)
- NIELS (observational, single-arm)
- Viscusi and Hanke 2015 (observational, single-arm)

=> No data on the comparison to BSC

Source: IQWiG Nutzenbewertung zu Vismodegib



# Vismodegib – G-BA

## ■ Studies included by Roche

- SHH4476g (ERIVANCE, Phase II, single-arm, pivotal)
- MO25616 (STEVIE, Phase II, single-arm)
- Study SHH4811g (US-EAP, Expanded access study, single-arm)
- Study SHH3925g (Phase I, single-arm)
- Extension study of patients from Phase I and II
- RegiSONIC (observational, single-arm)
- NIELS (observational, single-arm)
- Viscusi and Hanke 2015 (observational, single-arm)

=> Clue for a minor benefit


Source: Tragende Gründe des G-BA zu Vismodegib



# Asfotase Alfa – G-BA assessment

- Long-term Enzym-replacement therapy in patients with hypophosphotasia (age < 18, orphan)
- Study program
  - Single-arm intervention trials (Methodological issues)
  - Historical comparisons with two observational studies not accepted
  - One RCT (ENB-009-10), placebo-controlled (high potential for bias due to open-label design, issues with statistical test strategies)
- Limited evidence available
  - => Prospective registry (EMA)
  - => Prospective registry data with all German patients (G-BA)

Source: Tragende Gründe des G-BA zu Asfotase alfa



# Sebelipase Alfa – G-BA assessment

- Long-term Enzym-replacement therapy in patients with LAL-deficite (orphan)
- Study program
  - Single-arm intervention trial (N=9)
  - Single-arm retrospective observational study (N=25)
- Limited evidence available
  - => Prospective registry (EMA)
  - => Prospective registry data with all German patients (G-BA)

Source: Tragende Gründe des G-BA zu Sebelipase alfa




# Idebenon – G-BA assessment

- Visual deficits with LHON
- Study program
  - RCT (RHODOS, Phase II, N=85), placebo-controlled, but methodological issues
  - RHODOS observational Follow-up
  - Expanded Access Programm
  - Historical Case Record Survey
- Limited evidence available especially on long-term safety
  - => Prospective registry (EMA)
  - => Prospective registry (G-BA, time-restriction 2 years)

Source: Tragende Gründe des G-BA zu Idebenon





# Pragmatic trials - a way out...?


- Pragmatic trial
  - Aim to maximize generalizability to a broader setting
  - Four domains
    - Study population
    - Setting of the trial
    - Operationalization of the intervention and chosen comparator
    - Outcome measure
  - Comparison of randomized groups of patients
    - That are similar to the target population
    - Setting as in real world

Source: Groebbee et al. 2017: Pragmatic trials and real world evidence: Paper 1. Introduction, J of Clin Epi 88: 7-13); GetReal Initiative



# Final remarks

- IQWiG and G-BA use data of the highest evidence level
- If RCTs or at least interventional trials are available, RWD will not be taken into account
- If for orphan drugs the available evidence is sparse, a registry may be demanded by G-BA
  - Strategic implications for the company with regards to set-up, timing, etc.
  - G-BA may be asked for advice early on, if a registry is requested by EMA



Thank you!